Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
Gregor
J C
JC
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000191:economics*; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000209:etiology; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D009853:Omeprazole / Q000031:analogs & derivatives; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D014481:United States
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D009853:Omeprazole